Halozyme Therapeutics, Inc.

Halozyme Therapeutics is a biotechnology company that develops and commercializes novel oncology therapies and drug delivery technologies. Its proprietary enzyme platform is used to enhance the subcutaneous delivery of biologic drugs. The company’s drug development pipeline and regulatory submissions inherently require animal testing as part of preclinical safety and efficacy studies. This is confirmed by its active registration with the USDA Animal and Plant Health Inspection Service (registration number 93-R-0519), which is required for facilities conducting animal research.

Published research on Halozyme-sponsored drug candidates, such as studies on recombinant human hyaluronidase, explicitly detail the use of animal models, including Yucatan miniature pigs, to evaluate drug distribution and injection performance. The company’s own regulatory filings acknowledge that health authorities may require animal testing for product approvals. As a biopharmaceutical company advancing disruptive therapeutic solutions, animal testing remains an integral and ongoing component of its research and development activities.